Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp

Bullboard Posts

Post by jwalliscaon Apr 03, 2020 6:44pm

96 Views

Post# 30877926

YIKES no N95 Masks; Awfully quiet! Silence is Golden

Mr. House Positions:

Yes, quite quiet...

Come to think of "quiet"... isn't Silence Golden according to The Tremeloes?

Silence is Golden - The Tremeloes

Well, just 78k of which 68k were on the alternate exchanges leaving 10k in two trades on The Vulture! Germany chipped in with 22k and The US of Hey no N95 Masks for Canada, 26k. The Baker's Dozen cents close today was an incremental improvement from yesterday's 12.5 cents.

As for "Spring Like" weekend... -8C as I type with overnight low of -13C and very light, fluffy snow... This is Cowtown... warmer next week!

I still maintain the "markets" have no idea about Sernova. This will continue until something major happens. SVA will then catapult from Junior Penny Wonder Land to something akin to what happened to BLU and TRIL. Both are pharmaceuticals with share prices going nowhere until they went somewhere. Every dog has its day in the sunshine. When it happens: Some Dog, Some Sunshine!

True BLU Quote, News, Charts etc.

A TRIL a minute Quotes, News Charts etc.

Excerpt (17 October 2019):

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells, such as human donor cells, corrected human cells and stem-cell derived cells, to improve the treatment and quality of life of people with chronic metabolic diseases. These diseases include insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.

It is self evident that The Pouch works best for diabetics without using immunosuppression. Sernova would not have gone into the FDA trial without having an advanced means to not use immunosuppression. This is detailed in presentations as later steps once the present part of the trial is completed. Results to date show The Pouch works, period.

Sernova Nov 2019 Presentation (see Slide 7)

I suggest there is a lot more substance to Sernova than any one of us knows. It is not only The Pouch, but its ability to deliver "whatever" from it safely and efficaciously. The Pouch AND advances with say stem cells using The Pouch as the delivery vehicle are what Sernova is about.

I continue to believe Sernova will be a winner. The last news, 24 March 2020, clearly demonstrated there's nothing wrong with anything it is working on right now and it alluded to stem cells too (now being used in a trial by an unrelated company to treat COVID-19). Notice the FDA trial continues!

Sernova Provides Corporate Update and Outlook for 2020

Excerpt:

Some of our key initiatives for 2020 include:

- Focusing on patient enrollment completion which includes Cell Pouch implantation and the continued advancement of our US Phase I/II Cell Pouch Clinical Trial;

- Evolving stem cell-derived islet technologies, with the end goal to provide an unlimited supply of stem cell-derived islet cells for the anticipated treatment of any person inflicted with insulin-dependent diabetes;

- Continuing the evaluation of alternative novel local immune protection technologies for therapeutic cells, to be used in conjunction with our Cell Pouch technologies, for potential in-licensing or acquisition;

- Advancing further IND enabling preclinical proof of concept studies for the treatment of postoperative hypothyroid disease;

- Developing additional collaborations with pharma companies; and

- Releasing results of our research through publications in peer-reviewed scientific journals and conferences.

"While COVID-19 has introduced uncertainties for all people and businesses worldwide, we are proactively evolving how we operate and are adopting alternative methods and approaches to enable us to carry on our business and the US Phase I/II Cell Pouch Clinical Trial with the goal of mitigating potential impact. We are also continuing to advance our scientific, clinical and business activities within the context of the COVID-19 situation and are committed to following the evolving guidelines recommended by WHO, CDC, and the Federal and Provincial Governments of Canada to protect the safety of our employees and families, collaborators and business partners," said Dr. Philip Toleikis. He continued, "Despite the current environment, we are focused and committed to build upon our recent clinical and preclinical program achievements towards further important advancements in 2020 to deliver long-term value to our shareholders."

Should The Pouch ever be found out by the unrelated company, Celularity, and used as the delivery vehicle for this Stem Cell vs COVID-19 trial, the sky is the limit. Approval has been given by the FDA for this trial by Celularity. The CNBC link gives more details on what is being faced etc.

https://techcrunch.com/2020/04/02/venture-backed-celularity-receives-fda-approval-for-early-trials-of-a-new-cell-therapy-for-covid-19/

https://www.cnbc.com/2020/03/31/cell-therapy-to-fight-covid-19-awaits-fda-approval-for-clinical-trial.html

Cheers and top weekend to you!

jwall

V:SVA - Sernova Corp. - https://www.sernova.com/

17:47:47 EDT

Sym-X	Bid - Ask			Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
SVA - V	1.5	0.125 · 0.13	44.5	0.13	+0.005	4.0	78.1	10	17	0.13 0.130.125	0.285 0.095	15:44:04	Mar 24	15 min RT 2¢
TSX-V - V	1.5	0.125 · 0.13	44.5	0.13	+0.005	4.0	10.0	1	2	0.125 0.130.125	0.285 0.095	15:44:04		15 min
NEO ATS - U				0.125			41.5	5	7	0.13 0.130.125		14:23:12		15 min
Alpha - A				0.125			10.0	1	1	0.125 0.125 0.125		15:37:21		15 min
Omega - O				0.125			11.0	1	3	0.13 0.130.125		14:29:03		15 min
CX2 - H				0.125			5.0	1	2	0.13 0.130.125		15:38:08		15 min
TriAct - M				0.125			0.6		2			Mar 18 09:44:25		15 min

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.

Recent Trades - Last 10 of 17

Time ET	Ex	Price	Change	Volume	Buyer	Seller	Markers
15:44:04	V	0.13	0.005	1,500	1 Anonymous	79 CIBC	K
15:38:08	H	0.125		1,500	1 Anonymous	1 Anonymous	K
15:38:08	V	0.125		8,500	83 Mackie	1 Anonymous	KL
15:37:21	A	0.125		10,000	1 Anonymous	7 TD Sec	K
14:29:03	O	0.125		1,500	1 Anonymous	33 Canaccord	K
14:28:53	O	0.125		7,000	1 Anonymous	33 Canaccord	K
14:23:12	U	0.125		9,500	1 Anonymous	9 BMO Nesbitt	K
14:23:12	M	0.125		250	2 RBC	9 BMO Nesbitt	E
13:24:22	U	0.125		10,500	1 Anonymous	2 RBC	K
13:24:22	U	0.125		3,500	2 RBC	2 RBC	K